Fundraising Fox
Vitara Biomedical
Philadelphia, US · Founded 2019 · Delaware corporation · 65 employees on LinkedIn · 5 known investors
Find your way into Vitara Biomedical
Sign up to see every warm intro you have to Vitara Biomedical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vitara Biomedical team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Vitara Biomedical develops medical technology for the care of extremely premature newborns. The company is rooted in neonatology research from Children's Hospital of Philadelphia.
Founders & leadership
JM
James McGloneSoftware Verification ManagerJames McGlone is an Executive Officer and Director at Vitara Biomedical, where he oversees software verification for regulated biomedical devices supporting neonatal care technology. He has experience in software testing, embedded systems, and cross-functional coordination across engineering, quality, and clinical workflows.
JK
Jeffrey KahnExecutive
JM
Jim McGloneFounder
Board
TT
Thomas TodorowBoard director
IR
Ian RatcliffeBoard director
MK
DN
Diem NguyenBoard director
TF
Ted FjallmanBoard director
AD
Arthur DantchikBoard director
AF
NH
Nelson HillBoard director
Investors · 5
First Spark Ventures, Llclisted by First Spark Ventures, LlcMenlo Park
How we know: First Spark Ventures, Llc's portfolio page · the VCSheet dataset · Not right? Tell us
GV (Google Ventures)listed by GV (Google Ventures)Mountain View · $250K – $50M
How we know: GV (Google Ventures)'s portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Khosla Ventureslisted by Khosla VenturesMenlo Park · $100K – $20M
How we know: Khosla Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$70M disclosed across 3 rounds · 2020–2024
▶$10MraisedOct 2024 · 9 investors · BiotechnologyRule 506(b)
▶$10MraisedOct 2024 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas TodorowDirector
- Ian RatcliffeDirector
- Manish KothariDirector
- Bernard LyonsExecutive Officer, Director
- Diem NguyenDirector
- Ted FjallmanDirector
- Offering amount
- $50M
- Amount sold
- $10M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$40MraisedDec 2023 · 9 investors · BiotechnologyRule 506(b)
▶$40MraisedDec 2023 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Diem NguyenDirector
- Manish KothariDirector
- Thomas TodorowDirector
- Ted FjallmanDirector
- Rosaleen OskanianExecutive Officer
- Bernard LyonsDirector
- James McGloneExecutive Officer, Director
- John KellyExecutive Officer
- Ian RatcliffeDirector
- Offering amount
- $90M
- Amount sold
- $40M
- Minimum investment
- $59K
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$20MraisedMay 2020 · 3 investors · BiotechnologyRule 506(b)
▶$20MraisedMay 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arthur DantchikDirector
- James McGloneExecutive Officer, Director
- Jeffrey KahnExecutive Officer
- Thomas TodorowDirector
- Diem NguyenDirector
- Nelson HillDirector
- Offering amount
- $30M
- Amount sold
- $20M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Vitara Biomedical went on to found or lead other companies.
Related companies · 5
CertaraCertara provides biosimulation software, modeling, and regulatory services that support drug discovery and development across discovery, preclinical, clinical, regulatory, and market access phases. It serves pharmaceutical and biotech organizations seeking to make data-driven decisions and streamline regulatory submissions.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Vitro BiopharmaVitro Biopharma is a biotechnology company developing Wharton's jelly-derived (umbilical cord) mesenchymal stem cell therapies for autoimmune diseases and inflammatory disorders. It manufactures its cell therapy product candidates under cGMP conditions with ISO 9001:2015 and ISO 13485:2016 certification for the immunology and inflammation market.
VISTERRA, INC.A biologics center of excellence focused on developing and delivering medicines to patients, operating as a subsidiary within the Otsuka pharmaceutical group.
Viridian TherapeuticsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
Companies working in the same space as Vitara Biomedical.
In the news
Frequently asked questions
- What does Vitara Biomedical do?
- Vitara Biomedical develops medical technology for the care of extremely premature newborns. The company is rooted in neonatology research from Children's Hospital of Philadelphia.
- Who are Vitara Biomedical's investors?
- Vitara Biomedical's investors include First Spark Ventures, Llc, GV (Google Ventures), Jazzya Investments, Khosla Ventures, Myelin VC.
- How much funding has Vitara Biomedical raised?
- Vitara Biomedical has disclosed $70M raised across 3 rounds.
- Where is Vitara Biomedical headquartered?
- Vitara Biomedical is headquartered in Philadelphia, US.